Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.43 |
| ▸ | EHMT1 | Q9H9B1 | 3/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | GSDMD | P57764 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | PHGDH | O43175 | 3/20 | 0.42 |
| ▸ | ALDH2 | P05091 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15323 | 0.78 | CA12 (0.56) | CA12CA1CA2CA9EHMT2 | |
| SCHEMBL9665272 | 0.77 | TAS2R38 (0.53) | CA12CA1CA2CA9EHMT2 | |
| SCHEMBL19311794 | 0.75 | — | — | |
| SCHEMBL9665479 | 0.74 | CA12 (0.46) | CA12CA1CA2CA9EHMT2 | |
| SCHEMBL10443252 | 0.69 | — | — | |
| SCHEMBL96554 | 0.67 | — | — | |
| SCHEMBL8663660 | 0.67 | — | — | |
| SCHEMBL14310995 | 0.67 | EHMT2 (0.39) | CA12CA1CA2CA9EHMT2 | |
| SCHEMBL21051277 | 0.67 | — | — | |
| Sulfurous Acid SCHEMBL29190752 | 0.67 | CA1 (0.43) | CA12CA1CA2CA9EHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8680100-B2 | Sulfonylhydrazide compounds for treating proliferative disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2014-03-25 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-03-15 | — | — | US | disclosed |
| EP-2370402-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | Synta Pharmaceuticals Corp. (US) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010065512-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065512-A2 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065206-A1 | COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS | PKD1, PKD2, PCNA | CA12 700/4885CA1 2522/4885CA2 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.